Shenzhen - Delayed Quote CNY
Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ)
3.8300
+0.1200
+(3.23%)
At close: May 23 at 3:04:16 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
5,712,161.2242
5,782,766.9287
6,108,854.6491
6,650,024.8823
7,670,525.0294
Cost of Revenue
2,688,787.3798
2,731,900.6177
2,803,386.9345
2,811,175.8619
3,226,758.5714
Gross Profit
3,023,373.8445
3,050,866.3110
3,305,467.7146
3,838,849.0204
4,443,766.4580
Operating Expense
2,778,597.9148
2,789,632.3319
2,667,037.3320
2,991,761.0170
3,309,594.6966
Operating Income
244,775.9297
261,233.9791
638,430.3826
847,088.0034
1,134,171.7614
Net Non Operating Interest Income Expense
-24,867.9268
-31,265.1109
-48,115.8222
-71,152.5490
-50,118.2397
Pretax Income
53,927.4193
53,984.5349
606,823.0729
716,371.2422
854,175.6223
Tax Provision
23,494.5558
31,038.2716
105,254.8149
95,136.7574
183,324.3150
Net Income Common Stockholders
23,676.1916
21,467.3227
506,631.4257
624,241.8105
687,316.9290
Basic EPS
0.01
0.01
0.17
0.21
0.23
Diluted EPS
0.01
0.01
0.17
0.21
0.23
Basic Average Shares
2,174,343.1270
2,146,732.2650
2,980,184.8570
2,972,580.0500
2,988,334.4740
Diluted Average Shares
2,174,343.1270
2,146,732.2650
2,980,184.8570
2,972,580.0500
2,988,334.4740
Total Operating Income as Reported
37,762.6888
35,436.3666
489,265.2198
712,519.6007
875,186.5217
Rent Expense Supplemental
--
1,547.1151
4,836.2163
3,991.2665
3,878.9746
Total Expenses
5,467,385.2946
5,521,532.9497
5,470,424.2666
5,802,936.8789
6,536,353.2680
Net Income from Continuing & Discontinued Operation
23,676.1916
21,467.3227
506,631.4257
624,241.8105
687,316.9290
Normalized Income
131,991.7096
166,085.9173
590,987.4871
697,259.8390
828,327.0317
Interest Income
13,652.6108
17,305.9985
19,311.2669
11,023.5011
11,379.3894
Interest Expense
34,639.6089
44,862.4155
61,573.7995
69,667.8124
50,104.0765
Net Interest Income
-24,867.9268
-31,265.1109
-48,115.8222
-71,152.5490
-50,118.2397
EBIT
88,567.0282
98,846.9504
668,396.8723
786,039.0546
904,279.6988
EBITDA
88,567.0282
445,464.7538
1,014,503.5024
1,092,836.7813
1,165,748.9018
Reconciled Cost of Revenue
2,688,787.3798
2,731,900.6177
2,803,386.9345
2,811,175.8619
3,226,758.5714
Reconciled Depreciation
--
346,617.8034
346,106.6301
306,797.7267
261,469.2030
Net Income from Continuing Operation Net Minority Interest
23,676.1916
21,467.3227
506,631.4257
624,241.8105
687,316.9290
Total Unusual Items Excluding Goodwill
-180,525.8633
-192,824.7929
-102,058.3013
-84,200.1162
-179,544.0971
Total Unusual Items
-180,525.8633
-192,824.7929
-102,058.3013
-84,200.1162
-179,544.0971
Normalized EBITDA
269,092.8915
638,289.5467
1,116,561.8037
1,177,036.8974
1,345,292.9988
Tax Rate for Calcs
0.0004
0.0003
0.0002
0.0001
0.0002
Tax Effect of Unusual Items
-72,210.3453
-48,206.1982
-17,702.2399
-11,182.0877
-38,533.9944
12/31/2021 - 10/30/2009
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade